DRAGONTROPIN 100IU

DRAGONTROPIN 100IU is a specialized recombinant research reagent utilized primarily to investigate the biochemical pathways of human growth hormone (HGH) signaling and the regulation of insulin-like growth factor 1 (IGF-1) synthesis. As a high-affinity ligand for the growth hormone receptor (GHR), it is a fundamental tool for exploring cellular proliferation, tissue regeneration, and metabolic reprogramming. Dragon Pharma provides DRAGONTROPIN 100IU (Somatropin) at a purity level of 99%+, specifically for use in in-vitro laboratory experiments and preclinical animal models.

Overview

In the realm of endocrinology and regenerative medicine, DRAGONTROPIN has become a primary instrument for investigators exploring the somatotropic axis. Known scientifically as recombinant human Growth Hormone (rhGH), this 191-amino acid polypeptide is identical to the natural hormone produced by the pituitary gland. Dragon Pharma provides DRAGONTROPIN 100IU at a minimum purity of 99%, ensuring that researchers have access to a high-grade Research Compound capable of producing reproducible and accurate data in complex biological models.

As scientific inquiry into age-related metabolic decline, musculoskeletal recovery, and protein synthesis expands, the need for high-stability GH analogs like Dragontropin has grown. This expanded profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of DRAGONTROPIN 100IU.

Molecular Characteristics and Chemical Profile

The structural integrity of Dragontropin is defined by its precise folding and disulfide bond formation, which allows it to dimerize growth hormone receptors and initiate intracellular signaling cascades.

• Chemical Identity: Recombinant Human Growth Hormone (Somatropin)
• Molecular Formula: C990H1529N263O299S7
• Molecular Weight: 22,125 Da (approx. 22.1 kDa)
• Purity: >99% (HPLC and SEC-HPLC verified)
• Form: Lyophilized powder
• Manufacturer: Dragon Pharma

Research Applications

The compound is utilized in various scientific investigative domains, including:

• IGF-1 Modulation: Mapping the hepatic synthesis and systemic secretion of Insulin-like Growth Factor 1.
• Myocyte Hypertrophy: Investigating the activation of the PI3K/Akt pathway for muscle tissue repair.
• Lipolysis and Lipid Metabolism: Studying the mobilization of free fatty acids from adipose tissue.
• Osteoblast Activity: Assessing the influence of GH on bone mineral density and collagen synthesis.
• Immune System Modulation: Evaluating the impact of GH signaling on T-cell maturation and thymic function.

Pathway and Mechanistic Context

The core value of DRAGONTROPIN 100IU in a laboratory setting is its ability to activate the JAK2/STAT5 Signaling Pathway. In a natural physiological state, GH binding to its receptor triggers the phosphorylation of Janus Kinase 2 (JAK2), which subsequently recruits Signal Transducers and Activators of Transcription (STAT).

The Somatotropic Axis

Upon activation by Dragontropin, the STAT5 protein translocates to the nucleus to induce the transcription of target genes, most notably the Igf1 gene.

Key Mechanistic Shifts:

• Anabolic Potentiation: Dragontropin facilitates increased nitrogen retention and amino acid uptake, providing a framework for studying protein synthesis.
• Insulin Sensitivity Modulation: It acts as a metabolic switch, often studied for its "anti-insulin" effects on glucose uptake in peripheral tissues.
• Cellular Longevity Research: Researchers use Dragontropin to observe how GH levels correlate with cellular senescence and the biological markers of aging.

Primary Research Applications

1. Growth Hormone Deficiency (GHD) and Developmental Models

Dragontropin is heavily utilized in studies involving pituitary insufficiency models. Statistics indicate that adult GHD affects approximately 1 in 10,000 individuals globally. In the United States, research into pediatric growth disorders shows that idiopathic GHD prevalence is roughly 1 in 3,500 children. Furthermore, data suggests that certain ethnic groups may show variations in height-standard deviation scores (SDS) when responding to GH, with some studies indicating that African American children may be referred for growth evaluation later than Caucasian counterparts, emphasizing the need for standardized research models.

2. Musculoskeletal Injury and Recovery

Known in research circles for its "tissue-remodeling" potential, Dragontropin is used to observe how ligamentous and tendinous tissues adapt to mechanical stress. Investigators study changes in collagen type I and III expression in preclinical models of acute injury.

3. Metabolic Syndrome and Adiposity

In metabolic research, Dragontropin is studied for its ability to reduce visceral adiposity. Research models focus on how GH-induced lipolysis can mitigate the complications of chronic obesity and metabolic dysfunction.

Form and Analytical Testing

At Dragon Pharma, the commitment to scientific accuracy begins with a rigorous manufacturing process using E. coli or mammalian cell expression systems.

• Stability and Purity: The compound is lyophilized to maintain tertiary structure and prevent aggregation, which can lead to immunogenicity in animal models.
• Rigorous Analytical Verification: Every batch undergoes Size-Exclusion Chromatography (SEC-HPLC) and Mass Spectrometry to confirm the correct 191-amino acid sequence and the absence of truncated fragments.